Previous Article | Next Article ![]()
Infection and Immunity, March 2002, p. 1530-1537, Vol. 70, No. 3
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.3.1530-1537.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Medicine,1 Research Services, Veterans Affairs Medical Center, Memphis, Tennessee 38104,3 Department of Medicine,2 Department of Anatomy, University of Tennessee, Memphis, Tennessee 381634
Received 6 August 2001/ Returned for modification 13 September 2001/ Accepted 15 November 2001
|
|
|---|
|
|
|---|
Colonization of the small intestine is a critical element in the pathogenesis of enterotoxigenic disease and is mediated, at least in part, by a heterogeneous group of antigenically distinct plasmid-encoded adhesins referred to as colonization factor antigens or coli surface antigens. At least 20 established or putative colonization factors have been identified in human ETEC strains to date (11). This heterogeneity has hampered ETEC vaccine development efforts. Previous studies have demonstrated that immunity directed against a single colonization factor antigen provides protection against strains expressing homologous molecules but not against strains expressing heterologous molecules (33). In recent studies of ETEC infections in Egypt, only 23% of ETEC isolates expressed an identifiable colonization factor (40). Studies to elucidate additional factors required for epithelial cell attachment by ETEC are therefore warranted, and such studies may provide new avenues for vaccine development.
We have recently demonstrated that enterotoxigenic invasion protein A (Tia), a 25-kDa outer membrane protein, is encoded on a 46-kb pathogenicity island of prototypical ETEC strain H10407 (24). Tia mediates attachment to and invasion into cultured epithelial cells of gastrointestinal origin (23). However, the molecular events involved in the interactions, as well as the specific epithelial cell surface target receptors for Tia, have not been determined.
A diverse group of bacterial, viral, and protozoan pathogens have been shown to interact with eukaryotic cells through surface proteoglycans (42), particularly heparan sulfate proteoglycans (HSPGs) (5). These cell surface glycosaminoglycans (GAGs) are abundant on eukaryotic cells and may facilitate the initial interaction with the host that is required for an organism to bind to other molecular targets (26). Duensing et al. have suggested that a number of bacteria utilize binding to sulfated proteoglycans as a molecular bridge to interact with a diverse array of mammalian heparin binding proteins (MHBPs) that collectively promote parasitism (18).
Tia exhibits structural homology with a family of proteins predicted to form an eight-stranded ß-barrel in the outer membrane. The group includes a number of virulence factors, including Ail (4, 37) and the opacity-associated (Opa) proteins of Neisseria, to which Tia is most closely related (3). The Opa adhesins are a complex group of outer membrane proteins that are variably expressed in Neisseria. The OpaA protein of Neisseria gonorrhoeae strain MS11 has previously been shown to interact with HSPG (12), whereas the majority of Opa proteins utilize carcinoembryonic antigen-related cellular adhesion molecules (7, 13, 51). In this study, we found that the Tia-mediated interaction with host epithelial cells occurs, at least in part, through association with cell surface sulfated proteoglycans and that, similar to OpaAMS11, Tia may also participate in more complex interactions involving eukaryotic heparin binding proteins.
|
|
|---|
Bacterial strains, plasmids, cell lines, and growth conditions.
Mammalian cell lines HCT-8 and CHO-K1 and CHO cell lines defective in proteoglycan synthesis, pgsA-745 and pgsD-677 (34), were obtained from the American Type Culture Collection (Table 1). HCT-8 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum. The CHO cell lines were grown in Ham's F-12 medium supplemented with 10% fetal bovine serum. In experiments in which ß-D-xylosides were used to inhibit glycosaminoglycan formation, cells were grown in the presence of 1 mM p-nitrophenyl-ß-D-xylopyranoside (Sigma), and then the media were replaced with fresh media without inhibitor before the cells were used. AAEC191A, which was the E. coli host background strain used in Tia-mediated adherence and internalization studies, is a
recA
fim derivative of E. coli K-12 that was previously described by Blomfield et al. (8). E. coli HB101 carrying pRI203, which contains the Yersinia invasin gene cloned by Isberg et al. (30), was supplied by Dennis Kopecko. Plasmid pET185 contains the tia gene cloned into the pHG165 vector plasmid (47), as previously described (23).
|
View this table: [in a new window] |
TABLE 1. Bacterial strains, plasmids, and eukaryotic cell lines used in this study
|
Invasion and adherence assays. Invasion and adherence assays were carried out as previously described (23). Briefly, bacteria were grown to the mid-logarithmic phase and added to monolayers at a multiplicity of infection of approximately 10:1. The invasion data below reflect the percentages of the initial inoculum recovered after the monolayers were washed and incubated with medium containing gentamicin (100 µg/ml) for 2 h and the eukaryotic cells were lysed with 0.1% Triton X-100 to release the intracellular organisms. The cell-associated bacteria were the organisms recovered after washing and lysis of the monolayers in the absence of gentamicin. In experiments involving exogenous GAG or serum, the additional components were added at the concentrations indicated below approximately 30 min prior to inoculation of the monolayers with bacteria. To assess the contribution of serum or its components to the bacterial interaction with host cells, monolayers were washed on the morning of the experiment, and the medium was replaced with serum-free RPMI 1640 supplemented with glutamine.
Preparation of purified rTia protein. Bases 76 to 753 of the tia gene, which lacks the signal peptide coding region, were amplified from H10407 genomic DNA by PCR using primers tia.BamHI.76 (5'-CGGGATCCGATGAGAGCAAAACAGGCTT-3') and tia.KpnI.753 (5'-GGGGTACCGAAATGATAAGTTACCCC-3'). The amplicon was then directionally cloned into the BamHI and KpnI sites of polyhistidine fusion expression plasmid pQE-30 (Qiagen). The resulting recombinant plasmid, pQE-30.tia, was sequenced to ensure that the construct was in frame. Following expression in E. coli M15 (50) carrying the pREP4 repressor plasmid (21), the polyhistine-tagged rTia protein was purified by nickel affinity chromatography from urea extracts. Aliquots of the purified protein were kept at -80°C prior to use.
Production of anti-Tia antisera. To prepare anti-Tia antisera, two New Zealand White rabbits weighing approximately 2 kg were injected with 100 µg of rTia mixed 1:2 with complete Freund's adjuvant; this was followed by additional injections after 4 and 8 weeks. Sera were harvested at time zero and after 12 weeks. To remove cross-reacting antibodies, anti-Tia sera were preabsorbed against E. coli proteins by using an immobilized E. coli lysate column (Pierce). The sera were kept at 4°C. Rabbit antisera were also raised against sp.tia76-94, a synthetic peptide representing a putative surface-exposed region of Tia, which was first coupled to keyhole limpet hemocyanin (52); 100 µg of the peptide-keyhole limpet hemocyanin conjugate was injected by using the protocol described above.
Binding of eukaryotic proteins to Tia. To demonstrate that heparin binds to Tia, triplicate wells of a 96-well plate were coated with either rTia or BSA in carbonate buffer at concentrations ranging from 1.25 to 5 pmol/ml. After binding overnight at 4°C, the plates were washed with PBS and blocked with 10% BSA in PBS containing 0.05% Tween 20; then heparin-albumin-biotin (10 µg/ml) in blocking buffer was added. A duplicate set of wells containing the substrates described above was treated with blocking buffer alone. After incubation for 2 h at 37°C, the plate was washed, and binding was detected by using a 1:4,000 dilution of horseradish peroxidase (HRP)-labeled mouse monoclonal anti-biotin antibody (Zymed) in blocking buffer and then the 3,3',5,5'-tetramethylbenzidine (TMB) substrate Kirkegaard & Perry Laboratories. Absorbance at 655 nm was determined. To obtain heparin binding to Tia in its native conformation, overnight cultures of AAEC191A(pET185) and AAEC191A(pHG165) were diluted in Luria-Bertani broth containing ampicillin (100 µg/ml) and grown to the mid-log phase. The bacteria were washed with PBS, resuspended in PBS containing 1% BSA and biotinylated heparin at a final concentration of 5 µg/ml, incubated on a rotating disk for 30 min at 37°C, and then washed extensively with PBS to remove unbound heparin. To inhibit the interaction of heparin with Tia on the bacterial surface, either synthetic peptides or antibodies raised against synthetic peptides were used. In peptide inhibition studies, bacterial pellets were first resuspended in PBS containing sp.tia76-94 (AVGYDFYQHYNVPVRTEVEC) or a control peptide, sp.sls10-30 (FSIATGSGNSQGGSYTPGKC) (supplied by James Dale's laboratory), at final concentrations of 0.4 to 4 pmol/liter. For antibody inhibition studies, pellets were resuspended in PBS containing 1:10 dilutions of either antipeptide or preimmune sera. Resuspended pellets were rotated at 37°C for 30 min prior to washing and incubation with biotinylated heparin as described above. Bacterial pellets containing bound proteins were boiled in 1x Laemmli buffer containing Benzonase, and this was followed by separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (31). Proteins were then transferred to nitrocellulose membranes, and biotinylated proteins were detected by using streptavidin-HRP and a chemiluminescent substrate (Pierce Supersignal West Pico).
Biotinylation of normal human serum (NHS) (provided by James Dale's laboratory), human vitronectin, and bovine fibronectin was carried out as described above. Bacteria were then resuspended in 950 µl of PBS containing 1% BSA and 50 µl of biotinylated NHS or vitronectin and fibronectin at final concentrations of approximately 25 µg/ml. The bacterial suspensions were then rotated at 37°C for 1 h and washed to remove unbound proteins. Binding of unlabeled vitronectin to E. coli recombinants expressing Tia was demonstrated by both immunofluorescence and immunoblotting assays. In the immunofluorescence assays, bacteria were incubated first with heparin (5 µg/ml) in PBS containing 1% BSA. After three washes with PBS, the bacteria were incubated with unlabeled purified human vitronectin (final concentration, 25 µg/ml) in PBS containing 1% BSA for 1 h. The bacteria were washed, incubated with rabbit polyclonal anti-human vitronectin antisera (Calbiochem, La Jolla, Calif.) for 1 h, and then incubated with AlexaFluor 594-labeled goat anti-rabbit antibodies and washed. Aliquots (10 µl) of the bacteria were placed on glass slides, air dried, and mounted by using Prolong antifade reagent (Molecular Probes, Eugene, Oreg.). The slides were allowed to dry overnight in the dark and were viewed the following morning with a Zeiss Axiophot fluorescence microscope. In the immunoblot experiments, vitronectin was bound to bacteria as described above, and bound proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and detected by using anti-vitronectin antisera followed by HRP-labeled goat anti-rabbit immunoglobulin G Fc (1:60,000).
|
|
|---|
![]() View larger version (48K): [in a new window] |
FIG. 1. Exogenous GAGs inhibit Tia-host cell interactions. (A) Heparin inhibits Tia-mediated invasion of HCT-8 epithelial cells by DH5 (pET185) (Tia+ recombinant). Tia- control wells contained the DH5 (pHG165) vector control strain. (B) Addition of heparan-sulfated GAGs (H, heparin; HS, heparan sulfate) inhibited interaction of HCT-8 cells with immobilized rTia, whereas addition of other GAGs (HA, hyaluronic acid; CSB, chondroitin sulfate B; CSC, chondroitin sulfate C) did not inhibit binding. The number of cells bound to rTia was determined by measuring the eukaryotic hexosaminidase enzyme content. Values were determined relative to the binding of untreated cells (control). The error bars indicate standard deviations. The value for background binding to BSA substrate was subtracted from the values shown. (Background binding accounted for less than 1% of the positive control value.)
|
![]() View larger version (25K): [in a new window] |
FIG. 2. Enzymatic removal of GAG residues with the heparin-specific GAG lyase heparinase I inhibits binding of HCT-8 intestinal epithelial cells to immobilized rTia, whereas pretreatment of cells with chrondroitinase ABC (c.ABC) has no effect. The results are expressed as percentages of treated and untreated HCT-8 cells bound, as determined by assaying for hexosaminidase in attached cells. The error bars indicate standard deviations. Results obtained with GAG lyase are compared with results obtained after preincubation of cells with exogenous heparin. The value for nonspecific binding of HCT-8 cells to BSA substrate was subtracted from the values shown. (Background binding accounted for less than 1% of the positive control value.)
|
, which also makes type I fimbriae (Fig. 3A). Treatment of HCT-8 cells with xylopyranosides resulted in a significant decrease in the ability of these cells to bind to immobilized rTia. Wild-type CHO-K1 cells adhered to rTia (Fig. 3B) and permitted Tia-mediated bacterial uptake and attachment (Fig. 3C). However, this was not true of mutant CHO cells with defects in enzymes required for proteoglycan biosynthesis. Neither CHO xylosyltransferase mutants (such as pgsA-745), which lack heparan sulfate and chondroitin sulfate, nor N-acetylglucosaminyl transferase mutants (such as pgsD-677), which produce excess chondroitin sulfate but no HSPG, bound to rTia as effectively as the wild-type CHO cells. (Neither the mutant nor parental cell lines exhibited significant binding to BSA control wells in these experiments.) Similarly, cells defective in proteoglycan synthesis had a decreased capacity for Tia-mediated bacterial attachment and uptake (Fig. 3C).
![]() View larger version (32K): [in a new window] |
FIG. 3. Optimal interaction of Tia with target epithelial cells requires production of eukaryotic cell surface GAGs. (A) Effect of xylopyranoside, an inhibitor of proteoglycan synthesis, on Tia-mediated interaction with HCT-8 cells. The values are the numbers of cell-associated bacteria (both adherent and internalized) as determined by lysis of monolayers 2 h after infection. Neither DH5 (pET185) (Fim+) nor AAEC191A(pET185) (Fim-) could efficiently interact with xylopyronoside-treated HCT-8 host cells; however, this had no effect on the interaction of HB101 (Fim-) bearing the cloned invasin gene on recombinant plasmid pRI203. (B) Binding of GAG-deficient cells to immobilized rTia. The values are percentages of bound xylopyranoside-treated HCT-8 cells (HCT8-xp) or mutant cells (pgsA-745, pgsD-677) relative to the number of bound parental cells (HCT8, CHO-K1). (C) Tia-mediated interaction with HCT-8 cells (HCT8), wild-type cells (CHO-K1), and GAG synthesis mutant cells (pgsA-745). Tia+ indicates that Tia recombinant strain AAEC191A(pET185) was used, whereas Tia- indicates that negative control strain AAEC191A(pHG165) was used.
|
(pET185) by 80% ± 3.4%. This peptide is nearly identical to the peptide used in the study of Tia topology of Mammarappallil and Elsinghorst, which showed that this region participates in the Tia-mediated interaction with epithelial cells (36). sp.tia76-94 (Fig. 4, lanes 5 and 6), as well as antibodies raised against this peptide (Fig. 4, lane 4), inhibited interaction of biotinylated heparin with bacteria expressing rTia. An unrelated control peptide (Fig. 4, lanes 7 and 8) or preimmune rabbit sera (Fig. 4, lane 3) had no effect on the binding of heparin to Tia. Together, these data suggest that putative surface epitopes of Tia that direct attachment to epithelial cells are similar, if not identical, to the epitopes involved in Tia-HSPG interactions.
![]() View larger version (17K): [in a new window] |
FIG. 4. Tia functions as a prokaryotic heparin binding protein. (A) Binding of heparin-albumin-biotin to immobilized rTia or to a Tia synthetic peptide (sp.tia76-94). Triplicate wells of a 96-well plate were coated with different concentrations of either rTia, sp.tia76-94, or BSA. Binding of heparin-albumin-biotin to substrate was detected with HRP-labeled mouse monoclonal anti-biotin antibody. The absorbance values are averages based on the data for triplicate wells minus the background absorbance values obtained from nonspecific binding of antibody to substrate alone (in the absence of heparin-albumin-biotin). The error bars indicate standard deviations. OD655, optical density at 655 nm. (B) Binding of heparin to rTia in its native conformation. Binding of biotinylated heparin to an E. coli recombinant carrying the vector control plasmid, AAEC195(pHG165) (lane 1), or to a strain bearing the tia expression plasmid, AAEC195(pET185) (lanes 2 to 8), was determined. Antibodies raised against the Tia synthetic peptide sp.tia76-94 inhibited binding of heparin (lane 4), whereas preimmune sera from the same rabbit had no effect (lane 3). Similarly, while sp.tia76-94 inhibited binding at concentrations of 0.4 and 4 pmol/liter (lanes 5 and 6, respectively), equimolar amounts of the unrelated control peptide sp.sls10-30 (lane 7, 0.4 pmol/liter; lane 8, 4 pmol/liter) did not inhibit binding.
|
(pET185) Tia recombinants but had no effect on the uptake of E. coli DH5
containing only the vector plasmid, pHG165. These results suggested that a component of normal serum might bind to the bacteria via Tia and facilitate their interaction with target host cells.
![]() View larger version (21K): [in a new window] |
FIG. 5. Normal serum enhances epithelial cell internalization of Tia-expressing E. coli recombinants. HCT-8 cells were the target cells used. Bar 1, AAEC191A(pHG165) vector control; bar 2, AAEC191A(pET185) tia recombinant in the absence of serum; bar 3, AAEC191A(pET185) tia recombinant with a 1:100 dilution of normal, preimmune rabbit serum (NS); bar 4, AAEC191A(pET185) tia recombinant in the presence of immune serum containing anti-rTia antibody ( Tia) (1:100) from the same rabbit.
|
![]() View larger version (53K): [in a new window] |
FIG. 6. Potential recruitment of eukaryotic heparan sulfate binding proteins by Tia. (A) Binding of biotinylated NHS proteins with molecular masses of approximately 220, 75, and 65 kDa to E. coli recombinants expressing tia [AAEC191A(pET185)] or bearing a vector control plasmid [AAEC191A(pHG165)]. Subsequent stripping of this blot and redetection of bound antigens with anti-fibronectin and anti-vitronectin specific antibodies revealed the bands at 220 kDa (fibronectin) and at 75 and 65 kDa (vitronectin), respectively (data not shown). (B) Binding of purified, biotinylated fibronectin to AAEC191A(pHG165) after preincubation with heparin (lane 1) and to AAEC191A(pET185) without additional heparin (lane 2) and following preincubation with heparin (5 µg/ml) and extensive washing prior to binding of fibronectin (lane 3). (C) Binding of purified, unlabeled vitronectin to a Tia recombinant strain but not to a control strain after preincubation with heparin (5 µg/ml), as detected in an immunoblot by using anti-vitronectin antibody. (D) Immunofluorescence detection of vitronectin binding to E. coli recombinants expressing Tia following preincubation with heparin. The Nomarski differential interference contrast (DIC) images show that roughly equivalent numbers of the AAEC191A(pHG165) tia-negative control (panel 1) and the AAEC191A(pET185) tia recombinant strain (panel 3) were examined by immunofluorescence. AAEC191A(pET185) readily bound unlabeled vitronectin (immunofluorescence image in panel 4), whereas AAEC191A(pHG165) could not bind vitronectin (panel 2).
|
|
|
|---|
The molecular events that surround Tia-mediated invasion in vitro have not previously been explored in detail. Interestingly, genes encoding proteins with considerable homology to Tia have been described for strains of Salmonella enterica serovar Typhimurium (28), as well as porcine ETEC strains (35) and other pathogenic E. coli strains (48). Similar to the tia gene in H10407, these tia-like genes are on large chromosomal elements (24). The precise function of the Tia homologues also remains undefined. Because Tia also exhibits significant homology with members of the Opa family, which are neisserial proteins that direct epithelial cell attachment and invasion, we sought to determine whether similar processes might govern the cellular interactions promoted by the corresponding proteins.
Both Tia and the Opa proteins belong to a family of outer membrane proteins with a structure predicted to form an eight-stranded transmembrane ß-barrel having four surface-exposed domains. Within this family, the structure-function relationships of the Opa proteins have been studied most extensively. The studies have revealed that a single strain of N. gonorrhoeae may possess 11 or 12 opa genes that undergo phase variations in expression, directed by unique recombination events (46). These different genes encode outer membrane proteins with considerable sequence variation in their surface-exposed epitopes (6, 9, 15). Among the Opa proteins, OpaA is unique in its ability to bind to HSPG. Furthermore, a surface domain of OpaA that is essential for the cooperative interaction with HSPG, hypervariable region 1, has recently been identified (27). Theoretically, the basic amino acid residues of the exposed regions are involved in electrostatic interactions with HSPGs.
Although some prokaryotic outer membrane heparin binding proteins possess consensus sequences that have been associated with heparin binding, such as the XBBXBX motif (45), a clear heparin binding motif was not found in the Tia sequence. In fact, Clustal alignments of Tia and the Opa proteins did not reveal a region uniquely conserved in Tia and OpaAMS11. These alignments suggest that the most highly conserved regions are in the regions predicted to be part of the transmembrane ß-sheet motifs. Optimal interaction of Tia with HSPGs may involve approximation of basic residues on exposed loops in the tertiary structure, as suggested previously for some eukaryotic proteins (10). Furthermore, recent data suggest that some prokaryotic ligands recognize specific arrangements in disaccharide units of proteoglycans (20). This may indicate that optimal binding to HSPGs involves a more intricate lock and key mechanism rather than simple electrostatic attraction.
Duensing et al. have proposed that interaction with sulfated polysaccharides may be a mechanism for bacteria to recruit an array of MHBPs (18). The various molecular bridges formed between surface proteins of the bacteria, GAGs, and MHBPs could provide a highly adaptive mechanism for modulating bacterium-host interactions, taking advantage of the binding of a limited number of bacterial surface proteins to ubiquitous mammalian polysaccharide molecules in various niches. Our data support the concept that Tia, a prokaryotic heparin binding protein, has the potential to participate in interactions with a number of MHBPs. For Tia, like the OpaA protein of N. gonorrhoeae, such interactions may be determined by the niche in which Tia is optimally expressed and, consequently, by the availability of an appropriate HSPG template and particular eukaryotic heparin binding proteins. Interestingly, previous studies of gonococci expressing OpaA have suggested that entry of these organisms into cells belonging to different cell lines is dependent on the interaction of this outer membrane protein with molecular complexes that include HSPG and extracellular matrix proteins, such as fibronectin or vitronectin (16, 18, 49). Also, several previous reports suggested that ETEC strains also bind to fibronectin (22, 25), as well as vitronectin (14), and that the interactions may play an important role in bacterial adherence. However, the precise nature of the interaction between ETEC and these extracellular proteins has not been defined yet. Our results suggest that Tia could interact with these and perhaps other MHBPs. However, understanding the precise role of these proteins in Tia-mediated adherence and invasion will require additional studies. In addition, although it is convenient to study epithelial cell invasion in vitro, this phenomenon may be the result of one of several potential Tia-mediated pathogen-host interactions and may obscure the precise role of Tia in the interaction between the bacteria and the intestinal epithelium.
While many pathogens have been shown to interact with HSPGs, potentially to promote adhesion, the precise roles of these proteins in the pathogenesis of infections remain undefined. Recent studies have suggested that organisms may utilize these interactions for more than simple adherence. Indeed, some organisms induce shedding of proteoglycans via specific proteases, and these soluble proteoglycans inactivate cationic antimicrobial peptides (39, 43). Such strategies could provide a powerful selective advantage for a pathogen. Additional studies involving Tia and similar molecules must take into account their potential interactions with multiple eukaryotic proteins and address other possible roles in addition to promotion of adherence to and invasion of epithelial cells.
This study was supported by grants from the Department of Veterans Affairs (to J.M.F. and D.L.H.), by institutional funds from the University of Tennessee, and by Research, Inc.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»